Abstracts tagged "epidemiologic methods and rheumatoid arthritis (RA)"

Abstract Number: 2180 • 2018 ACR/ARHP Annual Meeting
Differences in Longitudinal Disease Activity Measures between Research Cohort and Non-Cohort Participants with Rheumatoid Arthritis Using Electronic Health Record Data
Milena Gianfrancesco¹, Laura Trupin¹, Charles McCulloch², Stephen Shiboski³, Jonathan Graf⁴, Gabriela Schmajuk⁵ and Jinoos Yazdany⁶, ¹Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ²Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, ³Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, ⁴Department of Medicine, Division of Rheumatology Zuckerberg San Francisco General Hospital, University of California, San Francisco, San Francisco, CA, ⁵San Francisco VA Medical Center, San Francisco, CA, ⁶University of California, San Francisco, San Francisco, CA
Background/Purpose: Research using electronic health records (EHR) may offer advantages over traditional observational studies, including lower costs and greater generalizability to a broader patient population;…
Abstract Number: 143 • 2017 ACR/ARHP Annual Meeting
Patient Rheumatoid Arthritis Data from the Real World (PARADE) Study: Preliminary Results from an Apple Researchkit™ Mobile App-Based Real World Study in the United States
Rachel Williams¹, Emilia Quattrocchi², Sarah Watts³, Sherry Wang⁴, Pam Berry⁴ and Michelle Crouthamel⁴, ¹Real World Evidence and Epidemiology, GSK, Collegeville, PA, ²R&D Immunoinflammation, GSK, Middlesex, United Kingdom, ³GSK, Stevenage, United Kingdom, ⁴GSK, Collegeville, PA
Background/Purpose: Smartphone apps and sensors enable researchers to design novel endpoints and collect real world data directly from patients in a cost-effective, fast, and patient-focused…
Abstract Number: 1991 • 2016 ACR/ARHP Annual Meeting
Risk of Incident Diabetes Mellitus and Its Association with Disease-Modifying Antirheumatic Drugs and Statins in Rheumatoid Arthritis
Gulsen Ozen^1,2, Sofia Pedro³, Marie Holmqvist⁴, Frederick Wolfe³ and Kaleb Michaud^2,3, ¹Rheumatology, Marmara University Faculty of Medicine, Istanbul, Turkey, ²Rheumatology, University of Nebraska Medical Center, Omaha, NE, ³National Data Bank for Rheumatic Diseases, Wichita, KS, ⁴Dept of Medicine, Clinical Epidemiology Unit, Dept of Medicine, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Diabetes mellitus (DM) is an important cardiovascular risk factor in RA. Although a few prior studies reported DM risk reduction with hydroxychloroquine (HCQ) and…
Abstract Number: 3196 • 2016 ACR/ARHP Annual Meeting
A Natural Language Processing System Can Capture Rheumatoid Arthritis Disease Activity Measures in US Veterans Across Multiple Sites
Grant W. Cannon¹, Shobhit Mehortra², Brett South², Ted R Mikuls³, Andreas M. Reimold⁴ and Brian C Sauer², ¹Veterans Affairs Salt Lake City Health Care System and University of Utah School of Medicine, Salt Lake City, UT, ²Salt Lake City VA and University of Utah, Salt Lake City, UT, ³Omaha VA and University of Nebraska Medical Center, Omaha, NE, USA, Omaha, NE, ⁴Rheumatology, Dallas VA and University of Texas Southwestern, Dallas, TX
Background/Purpose: The retrieval of rheumatoid arthritis (RA) disease activity measures recorded in an electronic medical record through natural language processing (NLP) would significantly aid…
Abstract Number: 29 • 2015 ACR/ARHP Annual Meeting
Development of Multimorbidity in Patients with Newly Diagnosed Rheumatoid Arthritis – a Population-Based Study
Helga Radner^1,2, Rishi Desai³, Theodore Tsacogianis⁴, Daniel H. Solomon⁵ and Seoyoung C. Kim⁶, ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²Department of Internal Medicine III; Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ³PharmacoEpidemiology & PharmacoEconomics, Brigham and Women's Hospital, Boston, MA, ⁴Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Boston, MA, ⁵Rheumatology, Brigham and Women's Hospital, Boston, MA, ⁶Medicine/Rheumatology, University of Pennsylvenia, Philadelphia, PA
Background/Purpose: Limited information exists whether RA patients are likely to develop more morbid conditions after RA diagnosis compared to those without RA and the…
Abstract Number: 1208 • 2015 ACR/ARHP Annual Meeting
How Well Do Acpas Discriminate and Predict RA in the General Population – a Study Based on 12,590 Population-Representative Swedish Twins
Aase Haj Hensvold¹, Thomas Frisell², Johan Askling² and Anca I Catrina¹, ¹Rheumatology Unit, Department of Medicine, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden, ²Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Anti citrullinated protein antibodies (ACPA) are highly specific for rheumatoid arthritis (RA), but the distribution and diagnostic accuracy of ACPA in general population has…
Abstract Number: 1228 • 2015 ACR/ARHP Annual Meeting
Estimating Under-Diagnosis of Rheumatoid Arthritis in Primary Care Data from the UK Clinical Practice Research Datalink
Julian Gardiner¹, Bowen Su¹, Benjamin Ellis² and Michael Soljak¹, ¹Department of Primary Care and Public Health, Imperial College London, London, United Kingdom, ²Arthritis Research UK, London, United Kingdom
Background/Purpose: The prevalence of rheumatoid arthritis (RA) in primary care electronic health records (EHRs) is much lower than patient self-reports from population surveys, which may…
Abstract Number: 1838 • 2014 ACR/ARHP Annual Meeting
No Increased Risk of Developing a First Invasive Melanoma in Rheumatoid Arthritis Patients Treated with Biologics: Results of a Collaborative Project of 11 European Biologics Registers
Louise Mercer¹, Johan Askling², Pauline Raaschou³, William Dixon¹, Lene Dreyer⁴, Merete Lund Hetland⁵, Lene Mellemkjær⁶, Anja Strangfeld⁷, Angela Zink⁸, Florenzo Iannone⁹, Axel Finckh¹⁰, Jakub Zavada¹¹, Helena Canhao¹², Fernando Martins¹³, Xavier Mariette¹⁴, Jacques Morel¹⁵, Jacques-Eric Gottenberg¹⁶, Adele Green¹, Victoria Hernández¹⁷, Florence Tubach¹⁸, Piet van Riel¹⁹, Kimme Hyrich²⁰ and Joachim Listing⁷, ¹The University of Manchester, Manchester, United Kingdom, ²Clinical Epidemiology Unit, Karolinska Institutet, Stockholm, Sweden, ³Karolinska Institutet, Stockholm, Sweden, ⁴Copenhagen University Hospital at Gentofte, Gentofte, Denmark, ⁵On behalf of all Depts of Rheumatology in Denmark, DANBIO, Glostrup Hospital, Glostrup, Denmark, ⁶Virus, Lifestyle and Genes, The Danish Cancer Society, Copenhagen, Denmark, ⁷German Rheumatism Research Center, Berlin, Germany, ⁸German Rheumatism Research Centre and Charité University Medicine, Berlin, Germany, ⁹Reumatologia Universita e Policlinico di Bari, Bari, Italy, ¹⁰Department of Medical Specialities, University of Geneva, Geneva, Switzerland, ¹¹Charles University, Prague, Czech Republic, ¹²Rheumatology Research Unit, Instituto de Medicina Molecular, Universidade de Lisboa, Lisbon, Portugal, ¹³Instituto de Medicina, Universidade de Lisboa, Lisbon, Portugal, ¹⁴rheumatology, Université Paris-Sud, Le Kremlin Bicêtre, France, ¹⁵Universite´ Montpellier, Montpellier, France, ¹⁶Department of rheumatology CHU, Strasbourg, France, ¹⁷BIOBADASER Registry, Madrid, Spain, ¹⁸INSERM, Universite Paris Diderot, Paris, France, ¹⁹Radboud University Medical Centre, Nijmegen, Netherlands, ²⁰Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom
Background/Purpose: Swedish and Danish national biologics registers (*) have reported a possible increase in melanoma risk with TNF inhibitors. Since melanomas are uncommon, the association…
Abstract Number: 2380 • 2014 ACR/ARHP Annual Meeting
Durability of First Biologic Is Not Influenced By Initial/Early DAS28
Gina Rohekar¹, Binu Jacob², Janet E. Pope³ and Claire Bombardier⁴, ¹Rheumatology, St. Joseph's Hospital, London, ON, Canada, ²University Health Network, Toronto General Research Institute, Toronto, ON, Canada, ³Medicine, Western University, London, ON, Canada, ⁴Rheumatology, University of Toronto, Toronto, ON, Canada
Background/Purpose: The Ontario Best Practices Research Initiative (OBRI) collects data on RA treatment in a real-world setting. Patients are enrolled and prospectively followed to…
Abstract Number: 2023 • 2014 ACR/ARHP Annual Meeting
Prevalence of Inflammatory Arthritis Conditions in the First Nations Population of Alberta
Cheryl Barnabe¹, C. Allyson Jones², Don Voaklander³, Deborah Marshall⁴, Christine Peschken⁵, Sasha Bernatsky⁶, John Esdaile⁷ and Brenda Hemmelgarn⁸, ¹Division of Rheumatology, University of Calgary, Calgary, AB, Canada, ²Departments of Physical Therapy and School of Public Health, University of Alberta, Edmonton, AB, Canada, ³University of Alberta, Edmonton, AB, Canada, ⁴University of Calgary, Calgary, AB, Canada, ⁵Medicine & Community Health Sciences, University of Manitoba, Winnipeg, MB, Canada, ⁶Divisions of Rheumatology and Clinical Epidemiology, McGill University Health Centre, Montreal, QC, Canada, ⁷Arthritis Research Centre of Canada, Richmond, BC, Canada, ⁸Division of Nephrology, University of Calgary, Calgary, AB, Canada
Background/Purpose: Canada's First Nations population reports higher rates of physician-diagnosed arthritis and rheumatism, and is known to have twice the rate of osteoarthritis. The prevalence…
Abstract Number: 2660 • 2013 ACR/ARHP Annual Meeting
Omega-3 Supplement Use Is Associated With a Reduced Risk Of Anti-Cyclic Citrullinated Protein Positivity In a Population Without Rheumatoid Arthritis, But At Risk For Future Disease
Ryan W. Gan¹, Kendra A. Young¹, Gary O. Zerbe², M. Kristen Demoruelle³, Michael H. Weisman⁴, Jane H. Buckner⁵, Peter K. Gregersen⁶, Ted R. Mikuls⁷, James R. O'Dell⁸, Richard M. Keating⁹, Michael J. Clare-Salzler¹⁰, Kevin D. Deane³, V. Michael Holers¹¹ and Jill M. Norris¹, ¹Epidemiology, Colorado School of Public Health, Aurora, CO, ²Biostatistics and Informatics, Colorado School of Public Health / University of Colorado Anschutz Medical Campus, Aurora, CO, ³Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, ⁴Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ⁵Benaroya Research Institute at Virginia Mason, Seattle, WA, ⁶Genomics and Human Genetics, Feinstein Institute for Medical Research, Manhasset, NY, ⁷Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ⁸Dept of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, ⁹Rheumatology Section, The University of Chicago, Chicago, IL, ¹⁰Experimental Pathology, University of Florida, College of Medicine, Gainesville, FL, ¹¹Rheumatology Division, University of Colorado School of Medicine, Aurora, CO
Background/Purpose: Rheumatoid arthritis (RA) is characterized by systemic inflammation and circulating autoantibodies, which can be present in serum years prior to RA diagnosis and can…
Abstract Number: 2421 • 2013 ACR/ARHP Annual Meeting
Association Between Physical Work Load and Rheumatoid Arthritis, Results From The EIRA Case Control Study
Annmarie Wesley¹, Henrik Källberg², Camilla Bengtsson², Eva Skillgate¹, Johan Rönnelid³, Mohammed Mullazehi⁴, Lars Klareskog⁵, Lars Alfredsson², Saedis Saevarsdottir⁶ and Sara Wedren^7,8, ¹Institute of Enviornmental Medicine, Karolinska Insitutet, Stockholm, Sweden, ²Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, ³Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden, ⁴Uppsala University, Uppsala, Sweden, ⁵Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ⁶Rheumatology Unit, Dept. of Medicine, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden, ⁷Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden, ⁸Department of Medicine, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: The association between occupation and RA has previously been investigated where occupations associated with a physical work load (quarry workers, construction workers, assistant nurses,…
Abstract Number: 2298 • 2013 ACR/ARHP Annual Meeting
Upper-Half Serum IgA (20+ TU/ml) and IgM (10+ IU/ml) Levels Significantly Predicted The Long-Term (mean 12 yrs) Onset Of Rheumatoid Arthritis When Combined, But Neither test Individually In Their Respective Full Ranges Of Values
Alfonse T. Masi¹, Azeem A. Rehman¹, Jean C. Aldag¹, Huaping Wang², Ned J. Goertzen³ and Marius C. Teodorescu⁴, ¹Medicine, University of Illinois College of Medicine at Peoria, Peoria, IL, ²Pediatrics, University of Illinois College of Medicine at Peoria, Peoria, IL, ³University of Illinois College of Medicine at Peoria, Peoria, IL, ⁴Microbiology, TheraTest Laboratories Inc, Lombard, IL
Background/Purpose: Serum rheumatoid factor (RF) is a major predictor of the new onset of rheumatoid arthritis (RA). In very early arthritis patients, higher titers…
Abstract Number: 1760 • 2013 ACR/ARHP Annual Meeting
Relationships Between Driving Distance, Rheumatoid Arthritis Diagnosis, and Disease-Modifying Anti-Rheumatic Drug Receipt
Jennifer M. Polinski¹, M. Alan Brookhart², John Z. Ayanian³, Jeffrey N. Katz⁴, Seo Young Kim⁵, Chris Tonner⁶, Edward H. Yelin⁷ and Daniel H. Solomon^8,9, ¹Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA, ²University of North Carolina, Chapel Hill, NC, ³Brigham and Women's Hospital, Boston, MA, ⁴Rheumatology and Orthopedics, Brigham and Women's Hospital, Boston, MA, ⁵Division of Rheumatology; Division of Pharmacoepidemiology, Brigham and Women's Hospital, Boston, MA, ⁶Medicine, University of California, San Francisco, San Francisco, CA, ⁷Arthritis Research Group, University of California, San Francisco, San Francisco, CA, ⁸Division of Pharmacoepidemiology, Harvard Medical School, Brigham and Women's Hospital, Division of Rheumatology, Division of Pharmacoepidemiology, Boston, MA, ⁹Division of Rheumatology, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Disease-modifying antirheumatic drugs (DMARDs) are recommended for all patients with rheumatoid arthritis (RA). Some studies estimate that almost half of patients with RA do…
Abstract Number: 926 • 2012 ACR/ARHP Annual Meeting
Accuracy of Canadian Health Administrative Databases in Identifying Patients with Rheumatoid Arthritis Using a Random Sample of 7500 Patients Seen in Primary Care
Jessica Widdifield¹, Claire Bombardier², Sasha Bernatsky³, J. Michael Paterson⁴, Jacqueline Young⁴, Diane Green⁴, J. Carter Thorne⁵, Noah Ivers¹, Debra Butt⁴, R. Liisa Jaakkimainen⁶, Myra Wang⁴, Vandana Ahluwalia⁷, George A. Tomlinson⁸ and Karen Tu⁴, ¹University of Toronto, Toronto, ON, Canada, ²Rheumatology, University of Toronto, Toronto, ON, Canada, ³Clinical Epidemiology, Research Institute of the McGill University Health Ctre, Montreal, QC, Canada, ⁴Institute for Clinical Evaluative Sciences, Toronto, ON, Canada, ⁵Southlake Regional Health Centre, Newmarket, ON, Canada, ⁶Preventive Med and Biostatisti, University of Toronto, Toronto, ON, Canada, ⁷William Osler Health Center, Brampton, ON, Canada, ⁸Dept of Medicine/Rheumatology, Toronto General Hospital, Toronto, ON, Canada
Background/Purpose: The use of population-based health administrative databases in rheumatology research is well established, but there are ongoing concerns about validity. To date, previous validation…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].